FDA Clearance Tracker · K200065
cobas Influenza A/B Nucleic acid test for use on the cobas Liat System, cobas Influenza A/B & RSV Nucleic acid test for use on the cobas Liat System, cobas Strep A Nucleic acid test for use on the cobas Liat System
Last checked: Nov 19, 2026Latest source record: Feb 10, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Feb 10, 2020
Substantially Equivalent
Time to decision
28 days
Received Jan 13, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K200065
- Device name
- cobas Influenza A/B Nucleic acid test for use on the cobas Liat System, cobas Influenza A/B & RSV Nucleic acid test for use on the cobas Liat System, cobas Strep A Nucleic acid test for use on the cobas Liat System
- Applicant
- Roche Molecular Systems, Inc.
- Applicant location
- Pleasanton, CA
- Received
- Jan 13, 2020
- Decided
- Feb 10, 2020
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3980
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OCC. The earliest in FDA's data is DEN070013, decided Jan 3, 2008.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K200065
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Roche Molecular Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260045 · Decided Aug 28, 2026 · 233 days after receipt
Device type: C. Difficile Toxin Gene Amplification Assay (OZN) · Laboratory Medicine & Pathology
K260047 · Decided Aug 28, 2026 · 233 days after receipt
Device type: Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System (PGX) · Laboratory Medicine & Pathology
- cobas® BV/CV510(k)
K260021 · Decided Jul 16, 2026 · 192 days after receipt
Device type: Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System (PQA) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.